VCYT

59.13

0.15% -0.09

Dopo l'orario di chiusura: 58.80 -0.33 -0.56%

Veracyte Inc (VCYT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$59.22

Aprire:

$57.06

Volume 24 ore:

2.01M

Relative Volume:

1.70

Capitalizzazione di mercato:

$4.72B

Reddito:

$541.74M

Utile/perdita netta:

$88.01M

Rapporto P/E:

54.44

EPS:

1.0862

Flusso di cassa netto:

$155.34M

1 W Prestazione:

+3.79%

1M Prestazione:

+15.29%

6M Prestazione:

+42.24%

1 anno Prestazione:

+144.14%

Intervallo 1D:

$57.06

$59.19

Intervallo di 1 settimana:

$55.62

$60.82

Portata 52W:

$22.61

$60.91

Veracyte Inc Stock (VCYT) Company Profile

Nome

Veracyte Inc

Settore

Healthcare (1092)

Industria

Diagnostics & Research (49)

Telefono

(650) 243-6300

Indirizzo

6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA

Dipendente

755

Cinguettio

@veracyte

Prossima data di guadagno

2026-07-30

Ultimi documenti SEC

VCYT's Discussions on Twitter

Compare VCYT vs TMO, DHR, IDXX, NTRA, A

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VCYT Veracyte Inc	59.13	4.73B	541.74M	88.01M	155.34M	1.0862
TMO Thermo Fisher Scientific Inc	532.48	201.86B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	203.83	145.10B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	567.44	45.44B	4.45B	1.10B	1.06B	13.59
NTRA Natera Inc	271.39	38.64B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	131.46	38.44B	7.23B	1.41B	1.09B	4.979

Veracyte Inc Stock (VCYT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-13	Iniziato	Jefferies	Buy
2025-12-02	Ripresa	Morgan Stanley	Underweight
2025-10-20	Iniziato	Canaccord Genuity	Hold
2025-03-20	Iniziato	Craig Hallum	Buy
2024-12-05	Downgrade	Goldman	Buy → Neutral
2024-11-15	Iniziato	Wolfe Research	Outperform
2024-10-16	Iniziato	UBS	Buy
2024-10-10	Iniziato	Guggenheim	Buy
2024-02-23	Reiterato	Needham	Buy
2023-01-18	Downgrade	Raymond James	Outperform → Mkt Perform
2023-01-05	Iniziato	Scotiabank	Sector Outperform
2022-01-07	Iniziato	Stephens	Overweight
2021-11-18	Ripresa	Goldman	Buy
2021-06-15	Iniziato	Raymond James	Outperform
2021-02-18	Ripresa	Needham	Buy
2021-01-28	Iniziato	Truist	Buy
2020-11-10	Iniziato	KeyBanc Capital Markets	Sector Weight
2020-09-09	Iniziato	Morgan Stanley	Underweight
2019-07-31	Iniziato	Lake Street	Buy
2019-07-02	Iniziato	Needham	Buy
2018-11-29	Downgrade	Janney	Buy → Neutral
2018-10-31	Aggiornamento	Janney	Neutral → Buy
2017-11-07	Downgrade	Janney	Buy → Neutral
2017-11-07	Downgrade	Piper Jaffray	Overweight → Neutral
2017-08-31	Ripresa	BTIG Research	Buy
2016-11-14	Ripresa	Leerink Partners	Outperform
2015-12-18	Iniziato	Cantor Fitzgerald	Buy
2015-06-11	Reiterato	Leerink Partners	Outperform
2013-11-26	Iniziato	William Blair	Outperform

Mostra tutto

Veracyte Inc Borsa (VCYT) Ultime notizie

Jul 16, 2026

This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm

Jul 16, 2026

Jul 15, 2026

A Look at Veracyte Inc (VCYT) After 5.1% Gain -- GF Value $38.30 vs Price $59.51 - GuruFocus

Jul 15, 2026

Piper Sandler Initiates Veracyte(VCYT.US) With Buy Rating, Announces Target Price $66 - Moomoo

Jul 15, 2026

Piper Sandler initiates Veracyte stock with overweight rating By Investing.com - Investing.com Nigeria

Jul 15, 2026

Piper Sandler Initiates Veracyte at Overweight With $66 Price Target - marketscreener.com

Jul 15, 2026

VCYT Initiated Coverage by Piper Sandler -- Rating Overweight - GuruFocus

Jul 15, 2026

Jul 14, 2026

CCORF Maintains Veracyte(VCYT.US) With Hold Rating, Raises Target Price to $60 - Moomoo

Jul 14, 2026

VCYT Maintained by Canaccord Genuity -- Price Target Raised to $60 - GuruFocus

Jul 14, 2026

Jul 12, 2026

Here's how much you'd have if you invested $1000 in Veracyte a decade ago - MSN

Jul 12, 2026

Jul 10, 2026

Morgan Stanley Maintains Veracyte(VCYT.US) With Sell Rating, Raises Target Price to $47 - Moomoo

Jul 10, 2026

Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026 - BioSpace

Jul 10, 2026

Jul 09, 2026

A Look at Veracyte Inc (VCYT) After 5.5% Gain -- GF Value $38.24 vs Price $59.30 - GuruFocus

Jul 09, 2026

VCYT Maintained by Morgan Stanley -- Price Target Raised to $47. - GuruFocus

Jul 09, 2026

Press Release: Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026 - Moomoo

Jul 09, 2026

St. Pete woman seeks $10M in discrimination lawsuit against employer - Business Observer

Jul 09, 2026

Veracyte, Inc. Stock 12‑Month Price Target Raised to $55.8, Implies 1% Downside - TradingView

Jul 09, 2026

Jefferies Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $70 - Moomoo

Jul 09, 2026

Does Veracyte’s (VCYT) Russell Value Index Debut Redefine Its Small-Cap Defensive Narrative? - simplywall.st

Jul 09, 2026

Jul 08, 2026

Veracyte Inc updates investors on breast cancer test coverage. Nasdaq-listed diagnostics group build - ad-hoc-news.de

Jul 08, 2026

All You Need to Know About Veracyte (VCYT) Rating Upgrade to Strong Buy - Yahoo Finance

Jul 08, 2026

Jul 07, 2026

Is Veracyte (VCYT) Fully Valued As Insider Selling And Index Additions Draw Attention? - simplywall.st

Jul 07, 2026

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy - AOL.com

Jul 07, 2026